Vistagen.com

VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical …

WEBPALISADE Phase 3 Program focused on PH94B’s potential as a rapid-onset, acute treatment of anxiety in adults with social anxiety disorder FDA Fast Track …

Actived: 3 days ago

URL: https://www.vistagen.com/news-releases/news-release-details/vistagen-announces-completion-palisade-1-phase-3-clinical-study

Vistagen Announces Positive Top-Line Results from Phase 3 …

WEBFirst positive U.S. Phase 3 study of an investigational therapy for social anxiety disorder in over 15 years. Statistically si gnificant rapid-onset reduction in patient …

Category: Health Go Health

PH80 Overview Vistagen Therapeutics, Inc

WEBPH80 Overview. PH80 is an odorless, tasteless synthetic investigational pherine with a novel, rapid-onset proposed mechanism of action (MOA) with potential to treat multiple …

Category: Health Go Health

VistaGen to Present PH94B Exploratory Phase 2A Research …

WEBSOUTH SAN FRANCISCO--(BUSINESS WIRE)--Jun. 2, 2022-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, central nervous …

Category: Health Go Health

Vistagen to Present Positive Fasedienol Phase 3 Data and Positive …

WEBPositive top-line results from fasedienol (PH94B) Phase 3 PALISADE-2 trial in social anxiety disorder (SAD) to be presented by SAD expert, Dr. Michael Liebowitz, at …

Category: Health Go Health

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the …

WEBKey study underway in registration-directed PALISADE Phase 3 program for fasedienol in social anxiety disorder Social anxiety disorder affects over 25 million …

Category: Health Go Health

Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 …

WEBLong-term intranasal administration of fasedienol, used as-needed up to four times a day in daily life, was safe and well-tolerated in nearly 500 patients with social …

Category: Health Go Health

Social Anxiety Disorder Vistagen Therapeutics, Inc

WEBSocial Anxiety Disorder. Based on the 2021 National Health and Wellness Survey, social anxiety disorder (SAD) affects over 25 million Americans, with onset typically in the mid …

Category: Health Go Health

Major Depressive Disorder Vistagen Therapeutics, Inc

WEBDepression is a serious medical illness and a global public health concern that can occur at any time over a person's life. According to the World Health Organization, depression is …

Category: Medical Go Health

AV-101, an Oral NMDR Glycine Site Antagonist for Depression and

WEBAV-101 (4-Cl-KYN) is an investigational oral prodrug that targets the N-methyl-D-aspartate receptor (NMDAR), an ionotropic glutamate receptor in the brain.

Category: Health Go Health

Investors Vistagen Therapeutics, Inc

WEBCompany Profile. Vistagen (Nasdaq: VTGN) is a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals …

Category: Health Go Health

Vistagen Awarded Mental Health America’s Platinum Bell Seal for

WEBMental Health America’s prestigious national certification complements Vistagen’s ongoing efforts to improve mental health care across the U.S. Timely …

Category: Health Go Health

Our Purpose, Our Vision

WEBThese core values guide our internal processes and define our mission to radically improve mental health and well-being worldwide. VistaGen Therapeutics’ core goal is to radically …

Category: Health Go Health

Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition

WEBAcquisition eliminates all future royalty payment obligations for PH94B and PH10 and expands Vistagen's pipeline. SOUTH SAN FRANCISCO, Calif.--(BUSINESS …

Category: Health Go Health

2024 RBC Capital Markets Global Healthcare Conference Vistagen

WEB2024 RBC Capital Markets Global Healthcare Conference. May 14 - May 15, 2024.

Category: Health Go Health

VistaGen Therapeutics Receives FDA Fast Track Designation for AV …

WEBSOUTH SAN FRANCISCO, CA -- (Marketwired) -- 01/03/18 -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company …

Category: Health Go Health

Stock Quote & Chart Vistagen Therapeutics, Inc

WEBDay's High. $4.81. Day's Low. $4.55. Volume. 194,805. Split Adjustment Factor. 1:1. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been …

Category: Health Go Health

Morgan Stanley 20th Annual Global Healthcare Conference

WEBMorgan Stanley 20th Annual Global Healthcare Conference. Sep 13 - Sep 14, 2022.

Category: Health Go Health

Top Categories

› Appendicitis

› Gout

› Women's Health

› Thyroid

› Sleep

› Skin

› Sexual Health

› Senior Health

› Oral Health

› Mental Health

› Men's Health

› Medications

› Lung Conditions

› Infectious Disease

Popular Searched

› Best healthy food cookbooks

› Better health shelby mi

› Optum american health network

› Access to health alder hey

› New health promotion strategies nursing

› Public health advertising campaigns

› E library for health contact

› World health insurance statistics

› Parkland health center bonne terre mo

› Carefirst trusted health plans

Recently Searched

› Mercy health lab southwest

› Pinnacle healthcare harrisburg pa

› Inpatient youth mental health facilities in iowa

› Uthealth hub application form

› Healthy meals with veggies

› Heart health tips american association

› Health care marketing techniques

› Roundup memorial health care mt

› Summit health athena portal

› Southeast health district folkston ga

The medical information found on the MedUSafe website is designed to support, not to replace the relationship between patient and physician and the medical advice they may provide.